Literature DB >> 12763927

ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases.

Randy D Gascoyne1, Laurence Lamant, Jose I Martin-Subero, Valia S Lestou, Nancy Lee Harris, Hans-Konrad Müller-Hermelink, John F Seymour, Lynda J Campbell, Douglas E Horsman, Isabelle Auvigne, Estelle Espinos, Reiner Siebert, Georges Delsol.   

Abstract

Expression of ALK protein by lymphoid cells and the description of variant anaplastic lymphoma kinase (ALK) translocations have typically been restricted to cases of T-cell and null anaplastic large-cell lymphoma (ALCL). All such cases result from a novel fusion created by the ALK gene on chromosome 2p23 and NPM on 5q35 or other variant translocation partners. A rare variant of diffuse large B-cell lymphoma (DLBCL), originally described in 1997, was thought to overexpress full-length ALK in contrast to a chimeric protein characteristic of ALCL. However, full-length ALK protein lacks tyrosine kinase activity and thus the mechanism of oncogenesis has remained elusive. We describe 6 cases of ALK+ DLBCL characterized by a simple or complex t(2;17)(p23;q23) involving the clathrin gene (CLTC) at chromosome band 17q23 and the ALK gene at chromosome band 2p23. All cases were studied using fluorescence in situ hybridization (FISH), complemented in one case with standard cytogenetic analysis, multicolor karyotyping (M-FISH), and reverse transcriptase-polymerase chain reaction. These results clearly demonstrate that most cases of ALK+ DLBCL share the same mechanism of deregulated ALK expression. Moreover, these results demonstrate the presence of CLTC-ALK fusions in these tumors and extend the list of diseases associated with this genetic abnormality to include classical T-cell or null ALCL, ALK+ DLBCL, and inflammatory myofibroblastic tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12763927     DOI: 10.1182/blood-2003-03-0786

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  55 in total

1.  Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Yasunori Ota; Yasunobu Sekiguchi; Satoko Hatano; Reimi Asaka; Masaaki Noguchi; Hiroyuki Mano
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

2.  Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas.

Authors:  Clare Bedwell; David Rowe; Deborah Moulton; Gail Jones; Nick Bown; Chris M Bacon
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

3.  A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.

Authors:  Mari Mino-Kenudson; Lucian R Chirieac; Kenny Law; Jason L Hornick; Neal Lindeman; Eugene J Mark; David W Cohen; Bruce E Johnson; Pasi A Jänne; A John Iafrate; Scott J Rodig
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

4.  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

Authors:  Anna V Galkin; Jonathan S Melnick; Sungjoon Kim; Tami L Hood; Nanxin Li; Lintong Li; Gang Xia; Ruo Steensma; Greg Chopiuk; Jiqing Jiang; Yongqin Wan; Peter Ding; Yi Liu; Fangxian Sun; Peter G Schultz; Nathanael S Gray; Markus Warmuth
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-21       Impact factor: 11.205

5.  Primary mediastinal anaplastic alk-1-positive large-cell lymphoma of T/NK-cell type expressing CD20.

Authors:  J Gonin; H Kadiri; S Bensaci; A Le Tourneau; T J Molina; J Diebold; D J Abdellouche; J Audouin
Journal:  Virchows Arch       Date:  2007-01-25       Impact factor: 4.064

Review 6.  Nodal aggressive B-cell lymphomas: a diagnostic approach.

Authors:  Sonam Prakash; Steven H Swerdlow
Journal:  J Clin Pathol       Date:  2007-03-16       Impact factor: 3.411

Review 7.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

Review 8.  ALK alterations and inhibition in lung cancer.

Authors:  Tri Le; David E Gerber
Journal:  Semin Cancer Biol       Date:  2016-09-13       Impact factor: 15.707

9.  Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy.

Authors:  Roger S Riley; David Williams; Micaela Ross; Shawn Zhao; Alden Chesney; Bradly D Clark; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 10.  Molecular diagnosis in lymphoma.

Authors:  Adam Bagg
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.